Fig. 3From: RIVA – a phase IIa study of rituximab and varlilumab in relapsed or refractory B-cell malignancies: study protocol for a randomized controlled trialOverview of translational samples. CxDx: Cycle x Day x, EOT end of trial, FU follow-up, PK pharmacokinetics, SCR screeningBack to article page